Carmell Therapeutics Financials
| CTCXW Stock | 0.03 0.01 26.76% |
Carmell |
Understanding current and past Carmell Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Carmell Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Carmell Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Carmell Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Carmell Therapeutics. Check Carmell Therapeutics' Beneish M Score to see the likelihood of Carmell Therapeutics' management manipulating its earnings.
Specialization | Healthcare, Biotechnology |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 02073F112 142922111 |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
Carmell Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Carmell Therapeutics's current stock value. Our valuation model uses many indicators to compare Carmell Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Carmell Therapeutics competition to find correlations between indicators driving Carmell Therapeutics's intrinsic value. More Info.Carmell Therapeutics is rated below average in number of shares shorted category among its peers. It is rated below average in ebitda category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Carmell Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Carmell Therapeutics Systematic Risk
Carmell Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Carmell Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Carmell Therapeutics correlated with the market. If Beta is less than 0 Carmell Therapeutics generally moves in the opposite direction as compared to the market. If Carmell Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Carmell Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Carmell Therapeutics is generally in the same direction as the market. If Beta > 1 Carmell Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Carmell Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Carmell has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Carmell Therapeutics' financials are consistent with your investment objective using the following steps:- Review Carmell Therapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Carmell Therapeutics' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Carmell Therapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Carmell Therapeutics' stock is overvalued or undervalued.
Carmell Therapeutics January 31, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Carmell Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Carmell Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Carmell Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Carmell Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Carmell Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 131.07 | |||
| Value At Risk | (39.47) | |||
| Potential Upside | 56.58 |
Additional Tools for Carmell Stock Analysis
When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.